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Background: Transthyretin amyloidosis (ATTR) is a rare, life-threatening systemic disorder. We 
present first findings on the cardiac hereditary ATTR in Poland. 
Methods: Sixty-eight consecutive patients with suspected or known cardiac amyloidosis were 
evaluated, including blood tests, standard 12-lead electrocardiography (ECG) and transthoracic 
echocardiography. ATTR was confirmed histologically or non-invasively using 99mTc-DPD 
scintigraphy. Transthyretin (TTR) gene sequencing was performed. 
Results: In 2017–2019, 10 unrelated male patients were diagnosed with hereditary ATTR. All 
patients had very uncommon TTR gene mutations: 7 patients had p.Phe53Leu mutation, 2 patients 
2 
had p.Glu109Lys mutation and 1 patient had p.Ala101Val mutation. The age of onset ranged from 
49 to 67 years (mean [SD] age, 58.7 [6.4] years). On ECG, most patients (70%) had pseudoinfarct 
pattern and/or low QRS voltage. The maximal wall thickness (MWT) on echocardiography varied 
considerably among the patients from moderate (16 mm) to massively increased (30 mm). Most 
patients (90%) had decreased LV ejection fraction (mean [SD], 43 [11] %). On follow-up, we 
observed progressive heart failure in almost all cases. The first patient with p.Phe53Leu mutation 
died of heart failure, the second died suddenly, the third successfully underwent combined heart and 
liver transplant with 15 months survival from the surgery. The patient with p.Ala101Val mutation 
died of stroke. 
Conclusions: According to available research, this is the first time types of TTR mutations and 
clinical characteristics of Polish patients with cardiac hereditary ATTR have been reported. Previous 
literature data about Polish background in families with p.Phe53Leu mutation and the present 
results, suggest that this TTR mutation might be endemic in the Polish population. 
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Transthyretin amyloidosis (ATTR) is a rare, life-threatening systemic disorder. It results 
from extracellular deposition of transthyretin (TTR)-derived amyloid fibrils leading to dysfunction 
of affected organs. It occurs in both a wild-type form (wtATTR) and a hereditary form (hATTR) 
transmitted in an autosomal dominant inheritance with a variable penetrance [1]. Without treatment 
the disease progresses gradually. According to recent reports, median survival of patients with 
cardiac ATTR is approximately 25 months to 41 months from onset of the first symptoms. The 
prognosis is worse in cases of hATTR [2]. 
More than 140 different disease-causing mutations of the TTR gene have been reported [3]. 
The prevalence of different mutations varies according to ethnicity and geographic region. Although 
there are endemic regions of ATTR such as Portugal, Sweden and Japan with certain high frequency 
mutations, the disease has been identified worldwide [1, 4–6].  
Transthyretin amyloidosis is known for its heterogeneity. Some TTR mutations induce 
cardiomyopathy as a main presentation while others are associated primarily with familial amyloid 
polyneuropathy. Other manifestations of hATTR often include gastrointestinal, renal and ocular 
symptoms as well as carpal tunnel syndrome [2, 7, 8]. The phenotypic expression can vary not only 
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among mutations but within mutations. The geographical origin and ethnic background of the 
patient can have implications for disease onset and initial symptoms for a given mutation [1]. 
Surprisingly, cases of monozygotic twins, in which one twin develops the disease and the other does 
not, have also been reported, proving that there are factors modulating amyloid fibrils formation [9, 
10]. 
Screening of the TTR gene and differentiation hATTR from wtATTR have serious clinical 
implications. In contrast to wtATTR, patients with hATTR may benefit from liver transplant or 
combined heart and liver transplant. Information on the type of TTR mutation also provides 
prognostic value not only for the proband but also for their family members. The spectrum of TTR 
gene mutations in Polish patients with cardiac ATTR and their clinical characteristics has never 
been described. Therefore, herein presented for the first time are the results of genetic testing and a 
description  of clinical heterogeneity of patients with cardiac ATTR diagnosed in the documented 
centers within the prior 3 years.  
 
METHODS 
The study complies with the principles outlined in the Declaration of Helsinki and was 
approved by the Institutional Ethics Committee.  
 
Study population 
The study included consecutive patients diagnosed with hereditary cardiac ATTR in 2017–
2019. 68 consecutive patients examined with suspected or known cardiac amyloidosis were referred 
to two cardiology centers for further evaluation. All patients underwent routine assessment 
including medical history, physical examination, blood tests with N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) and high-sensitive cardiac troponin T (hs-cTnT) measurements, as well as 
standard 12-lead electrocardiography (ECG) and transthoracic echocardiography. ATTR was 
confirmed histologically with immunohistochemistry and/or non-invasively (intensive cardiac 
uptake at 99mTc-DPD bone scintigraphy) [11]. Light chain amyloidosis was excluded by free light 
chain testing: conventional electrophoresis and immunofixation of serum or urine. Patients 
underwent TTR gene sequencing as part of their routine workup. Neurological assessment was 
performed in all patients with hATTR. Informed written consent was obtained from each participant 
included in the study. 
 
Analysis of TTR gene 
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Patients assessed at the Institute of Cardiology, Warsaw, Poland underwent genetic testing in 
a local laboratory. Genomic DNA in all patients was extracted from whole blood leukocytes with 
the salting-out method. The entire coding regions of the TTR gene together with splice sites were 
sequenced with the Sanger method using a 3130xL Genetic Analyzer (Life Technologies, Foster 
City, California, United States) and the Big Dye Terminator v1.1 Cycle Sequencing Kit (Life 
Technologies) according to manufacturer instructions. For chromatograms analysis Variant Reporter 
1.1 (Life Technologies) was used. All patients from both centers also underwent commercially 
available TTR genetic testing developed and performed by Centogene AG, Rostock, Germany.  
 
RESULTS 
Of the 68 patients, 10 (14.7%) male patients had cardiac hATTR, 19 (27.9%) had wtATTR, 
9 (13.2%) were diagnosed with cardiac light chain amyloidosis and 30 (44.1%) had no evidence of 
amyloid deposition. All patients with hATTR had very uncommon TTR gene mutations: 
p.Phe53Leu (NM_000371.3:c.157T>C, rs121918068), p.Glu109Lys (NM_000371.3:c.325G>A) 
and p.Ala101Val (NM_000371.3:c.302C>T). The most prevalent was p.Phe53Leu mutation 
identified in 7 out of 10 patients with hATTR. The baseline clinical data of the patients with hATTR 
was shown in Table 1.  
The age of onset ranged from 49 to 67 years (mean [SD] age, 58.7 [6.4] years) and differed 
considerably even among patients with the same mutation. Family history suggestive of cardiac 
amyloidosis was positive in 6 probands. On the ECG, most patients (70%) had a pseudoinfarct 
pattern in precordial leads. Similarly, most patients (70%) had low QRS voltage in limb leads. 
Echocardiography revealed concentrically increased thickness of the left ventricular (LV) wall in all 
patients. The maximal wall thickness (MWT) varied markedly among the patients from moderate 
(16 mm) to massively increased (30 mm) (mean [SD] MWT, 22 [4] mm). Most patients (90%) had 
decreased LV ejection fraction (LVEF) (mean [SD] LVEF, 43 [11] %). Baseline laboratory 
examination revealed increased levels of hs-cTnT and NT-proBNP in all patients. Even individuals 
with initially mild symptoms of heart failure (HF) had elevated serum concentrations of examined 
biomarkers (Fig. 1).  
Seven patients presented with mixed-phenotype and suffered also from polyneuropathy. 
Only 2 patients primarily presented with polineuropathy (patients with p.Phe53Leu mutation) and 
cardiac assessment was performed after familial amyloid polyneuropathy was confirmed. Five other 
patients were diagnosed with polyneuropathy during follow-up. Of the 10 patients, 7 suffered from 
gastrointestinal disturbances. However, it was difficult for the patients to determine at what stage of 
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the disease the first symptoms from the gastrointestinal tract appeared and whether they preceded 
the appearance of cardiac manifestations. Five patients presented with carpal tunnel syndrome, the 
so-called ‘red flag’ symptom for ATTR, which evidently preceded the appearance of cardiac 
symptoms. One of the patients had ocular symptoms, which seem to occur frequently in patients 
with  p.Glu109Lys mutation. Orthostatic hypotension was present in 4 patients with advanced 
symptoms of HF regardless of the presence of polyneuropathy. 
 
Clinical characteristics of patients with p.Phe53Leu TTR mutation 
Although the patients with p.Phe53Leu TTR mutation had heterogeneous clinical 
presentation and were diagnosed at various stages of the disease, ranging from accidentally 
discovered disease in asymptomatic patient to the advanced stages of biventricular HF, all of them 
had significant abnormalities on ECG and echocardiography from the first assessment. It is 
noteworthy that all patients except for proband 6, who was diagnosed at a very early stage of the 
disease, had reduced LV systolic function. Interestingly, symptoms of HF assessed in accordance to 
the New York Heart Association (NYHA) classification, did not reflect the impairment of LV 
systolic function, patients with only mild symptoms of HF had already significantly impaired LVEF 
(Fig. 2). Most of the patients with p.Phe53Leu mutation (71.4%), except for 2 cases, presented with 
mixed phenotype and had also polyneuropathy at various stages of advancement. 
The case of proband 3 is particularly interesting as a male patient was diagnosed with 
hATTR at a time when he was completely asymptomatic with good exercise tolerance confirmed. 
He was referred for cardiological assessment due to ECG abnormalities found during annual 
medical check-up (sinus rhythm with low QRS voltage in the limb leads and nonspecific ST-T wave 
changes). Physical examination and chest X-ray were normal. However, baseline levels of NT-
proBNP and hs-cTnT were significantly increased from the beginning. Echocardiography revealed 
moderately increased LV wall thickness (MWT 16 mm), mildly enlarged left atrium and 
significantly reduced LV systolic function without segmental hypokinesis (LVEF 40%). Moreover, 
coronary computed tomography angiography, performed to reveal the reasons for the impaired 
LVEF, showed right coronary artery (RCA) chronic total occlusion as well as stenosis in the left 
main coronary artery, in the left anterior descending artery (LAD) and in the left marginal artery. 
The patient was diagnosed with occult multivessel coronary artery disease. Invasive coronary 
angiography with fractional flow reserve demonstrated that only stenosis in the LAD was 
hemodynamically relevant. Percutaneous coronary intervention using drug eluting stents was 
performed for occlusion in the RCA and for stenosis in LAD. Although at 20-month follow-up, the 
patient remained asymptomatic, with good exercise tolerance confirmed on ECG exercise testing, 
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further deterioration of LV function and a significant increase of cardiac biomarkers were observed. 
HF symptoms progressed rapidly, however signs of polyneuropathy never appeared in this patient. 
Ultimately, the patient underwent successful combined heart and liver transplantation.  
Interestingly, proband 1, a 64-year-old male with advanced biventricular HF, also had 
ischemic heart disease and was treated with coronary artery bypass graft surgery. The patient had 
many comorbidities, including atrial fibrillation (AF) with third-degree atrioventricular block 
requiring pacemaker implantation, subsequently upgraded to cardiac resynchronization therapy, 
polyneuropathy grade 1 (he was able to walk without aid), recurrent pleural effusion and bilateral 
carpal tunnel syndrome. 
 
Clinical characteristics of patients with p.Glu109Lys TTR mutation 
Two patients with features of restrictive cardiomyopathy and carpal tunnel syndrome were 
identified with the p.Glu109Lys TTR mutation. Proband 8, a 49-year-old male, was diagnosed at a 
very early stage of the disease (NYHA class I), without overt signs of HF, with only mildly 
increased levels of cardiac serum biomarkers. However, echocardiography and ECG demonstrated 
significant abnormalities, including mildly reduced LV systolic function, restrictive LV filling 
pattern, small pericardial effusion as well as pseudoinfarct pattern and low QRS voltage in limb 
leads. The patient had a family history suggestive of cardiac amyloidosis.  
A  second patient with p.Glu109Lys TTR mutation, proband 9, was referred to the 
documented institution due to a 3 month history of progressive exertional dyspnea (NYHA class III 
at initial presentation) and massive lower-limbs edema. He also suffered from periorbital purpura, 
weight loss, mild symptoms of polyneuropathy (predominantly paresthesias) and ocular symptoms 
including vitreous opacities. His family history was unremarkable. ECG demonstrated occult AF of 
unknown duration, pseudo-infarct pattern, nonspecific ST segment and T-wave abnormalities. QRS 
voltage was in the lower range of the norm. The chest X-ray showed pulmonary congestion and 
small left sided pleural effusion. Echocardiography revealed increased LV wall thickness (max. 23 
mm at interventricular septum), sparkling echoes, restrictive LV filling pattern and decreased LVEF 
45%. Right ventricle (RV) was enlarged with increased wall thickness. Both atria were augmented 
and small pericardial effusion was present. Diagnosis of ATTR was confirmed with bone 
scintigraphy with 99m-DPD tracer (Fig. 3A–D). Two months after initial presentation the patient 
was stable but with a further increase in NT-proBNP and hs-cTnT levels (3513 pg/mL and 68 ng/L, 
respectively). He was referred for compassionate treatment with tafamidis as a bridge to combined 
heart and liver transplantation. 
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Clinical characteristics of patients with p.Ala101Val TTR mutation 
Only 1 patient, 67-year-old male with progressive HF (NYHA class II/III at initial 
presentation), permanent AF, significantly increased levels of cardiac biomarkers was identified 
with p.Ala101Val TTR mutation. Echocardiography of this patient showed massively increased RV 
and LV wall thickness (max. 27 mm at interventricular septum), significantly decreased LV systolic 
function (LVEF 35%) and small pericardial effusion. The patient also suffered from orthostatic 
hypotension, bilateral carpal tunnel syndrome mild symptoms of polyneuropathy and monoclonal 
gammapathy of unknown significance. Due to the presence of only microdeposits of amyloid in the 
tissue biopsy and no access to 99mTc-DPD scintigraphy at that time, diagnosis of ATTR in the 
patient was established using mass spectrometry. 
 
Follow-up 
 Information about the outcome of patients with hATTR are collected in Table 1. In almost 
all cases progressive HF was observed. One patient with p.Phe53Leu TTR mutation (proband 1) 
died of biventricular HF, proband 2 died due to sudden cardiac death, proband 3 successfully 
underwent combined heart and liver transplantation with 15 a month survival from the surgery. One 
patient with p.Glu109Lys TTR mutation, proband 9, is currently waiting for combined heart and 
liver transplantation. Patient with p.Ala101Val TTR mutation (proband 10) died of stroke. 
 
DISCUSSION 
Herein, reported for the first time, types of TTR mutations and clinical characteristics of 
Polish patients with cardiac hATTR. Currently, literature data on Polish patients with cardiac 
amyloidosis concerns mainly light chain amyloidosis and consists of only a few case reports and 
two original papers [11–15]. The presented study, although based on the small cohort of patients 
from two cardiology centers, fills an important gap in diagnosis and clinical management of cardiac 
ATTR in Poland. This research highlights that improvements in diagnostics, in particular 
introducing genetic analysis of the TTR gene and 99mTc-DPD scintigraphy into a routine diagnostic 
path of patients with suspicion of ATTR, hugely facilitates diagnostics. Moreover, it allows 
establishment of a non-invasive diagnosis [8, 16]. It is crucial to identify patients with ATTR, 
especially now, when the targeted treatment of ATTR is possible. 
In the present study, patients were reported with unexpectedly rare TTR mutations: 
p.Phe53Leu, p.Ala101Val and p.Glu109Lys. Surprisingly, none of the most prevalent TTR variants: 
p.Val50Met, p.Val142Ile or p.Thr80Ala [4, 17, 18], were identified. Moreover, a high incidence of 
p.Phe53Leu TTR mutation were observed. This occurred in the majority of the patients (70%).  
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The phenylalanine 53 is highly conserved amino acid of the TTR protein across species [19]. 
Position 53 of TTR protein is not directly involved in the formation of the transthyretin tetramer, 
however, loss of an aromatic ring associated with phenylalanine, may change the molecule 
conformation and lead to fibril formation [20]. The p.Phe53Leu TTR mutation was described 
previously only in 7 unrelated families including 2 American families of Polish descent and single 
Swedish, Taiwanese, Chinese, Hungarian and Israeli families [19–25]. This mutation was associated 
mostly with late-onset, progressive polyneuropathy and simultaneous presentation of severe 
cardiomyopathy. Previous data in the literature about a Polish background in families with 
p.Phe53Leu mutation and present findings (another 7 unrelated Polish families identified with 
p.Phe53Leu mutation) imply that this TTR mutation might be very frequent in the Polish population 
[20, 21]. Of note, almost all of the patients with p.Phe53Leu mutation presented in this study 
(85.7%) were of south Poland origin, suggesting that this might be an endemic region, where 
p.Phe53Leu mutation is found with high frequency. It is also possible that this rare mutation was 
introduced into the population by a common ancestor. However, based on available data it is not 
possible to prove so-called “founder effect”. The heterogeneous clinical presentation of the patients 
with p.Phe53Leu TTR mutation (different age of onset, concomitant polyneuropathy but not in all 
cases) suggests also that other genetic or environmental factors may be involved in the disease 
development and progression. 
p.Glu109Lys TTR mutation was reported previously only in three families and is 
characterized by early onset, concomitant ocular manifestation and severe phenotype with early 
heart dysfunction leading to heart and liver transplantation [26–28].A similar course of the disease 
was observed in the case of proband 9, including the rapid progression of HF and ocular 
manifestations. 
p.Ala101Val TTR mutation is an unusually rare mutation. So far, only 2 patients were 
previously reported with this mutation, including 1 patient from Institute of Cardiology who was 
diagnosed genetically in the National Amyloidosis Center in London in 2008 [17]. The patient 
suffered from severe biventricular HF with massive leg edema, persistent pericardial and pleural 
effusion requiring recurrent hospitalizations. ECG demonstrated sinus rhythm, first degree 
atrioventricular block (PR 320 ms), low QRS voltage in limb leads and regression of r waves in 
lateral (V5–V6) leads. Echocardiography demonstrated features of restrictive cardiomyopathy with 
concentrically increased LV wall thickness (max. 15 mm), moderated LA enlargement and mildly 
decreased LV systolic function (LVEF 50%). During follow-up, further deterioration of LV function 
was observed (LVEF 38%) as well as features of moderate pulmonary hypertension (PASP 40 
9 
mmHg), thickening of RV wall and dilatation of both atria. The  patient died of advanced HF while 
awaiting heart transplantation. 
In the present study, in line with the previous literature data, cardiac biomarkers are very 
sensitive for diagnostic and prognostic purposes were observed [29]. Even patients with only mild 
symptoms of HF (NYHA I) or asymptomatic patients, had already elevated serum levels of cardiac 
biomarkers (Fig. 1).  
 
CONCLUSIONS 
The high prevalence of p.Phe53Leu TTR mutation in the study group and in previous 
literature data suggest that a possible endemic mutation has been found among Polish patients with 
cardiac hATTR. Considering the fact that the diagnosis of cardiac hATTR has clinical implications 
and information on the presence of TTR mutation is useful for affected patients, pre-symptomatic 
carriers and their relatives, patients  should be identified with this disorder to better define this 
disease. The emergence of novel treatments in cardiac ATTR, which may improve patient prognosis 
is another argument for the intensification of epidemiological and cross-sectional studies like this. 
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Table 1. Baseline clinical characteristics and outcome of patients with hereditary transthyretin (TTR) amyloid cardiomyopathy. 





p.Phe53Leu p.Phe53Leu p.Phe53Leu p.Phe53Leu p.Phe53Leu p.Glu109Lys p.Glu109Lys p.Ala101Val 
Age of onset 64 57 49 58 64 55 66 49 57 67 
NYHA class III/IV I I II IV I III II III II/III 
Positive family history  + + – – + + + + – – 




SR SR SR SR AF, nsVT SR AF AF 
Low QRS voltage NA + + + + + – + – + 
Pseudoinfarct pattern NA  + – – + + + + + + 
NT-proBNP [pg/mL] 10954 1199 925 1049 10780 191 13541 394 2340 6070 
hs-cTnT [ng/L] 103 98 28 51 122 26 136 19 50 78 
MWT [mm] 30 20 16 18 25 20 20 24 23 27 
Increased RV wall thickness + – – + – – – – + + 
LVEF [%] 30 40 40 55 40 62 29 55 45 35 
Restrictive LV filling 
pattern 
– – + – + – – + + – 
Pericardial effusion + – – – + – + + + + 
Orthostatic hypotension  + – – – + – + – – + 
Polyneuropathy + + – + – + + – + + 
CNS manifestations + – – – – + + – – + 
Small fiber neuropathy + + – + – + + – + + 
Gastrointestinal + + – – + + – + + + 
13 
manifestations 
Ocular manifestations – – – – – – – – – + 
Biceps tendon rapture – – – – + – – – – – 
Chronic kidney disease – + – – + – + – – – 
Carpal tunnel syndrome + + – – – – – + + + 
Outcome Death at 
age of 67 
due to HF 




















Death at age 
of 71 due to 
stroke 
AF — atrial fibrillation; CNS — central nervous system; ECG — electrocardiogram; HF — heart failure; hs-cTnT — high-sensitivity cardiac troponin T; LV — left ventricular; 
LVEF — left ventricular ejection fraction; MWT — maximal wall thickness; NA — not applicable; nsVT — nonsustained ventricular tachycardia; NT-proBNP — N-terminal pro-B-





Figure 1. Baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP; normal range: 0–125 pg/mL) and high-sensitive cardiac troponin T (hs-
cTnT; normal range: 0–14 ng/L) levels in the patients classified according to the New York Heart Association classification of heart failure. 
 
Figure 2. Left ventricular ejection fraction in the patients classified according to the New York Heart Association classification of heart failure. 
 
Figure 3. Clinical data of proband 3; A. Standard 12-lead electrocardiogram; B. Chest X-ray; C. Transthoracic echocardiography; D. Bone 
scintigraphy with 99mTc-DPD tracer confirming transthyretin amyloid cardiomyopathy in anterior (left) and posterior (right) whole body scan. 
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